Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633355 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
NCT05633355 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 187 participants.
The verdict
NCT05633355, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
Interventions
- DRUG Rocatinlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05633355
The ClinicalTrials.gov registry entry for NCT05633355 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rocatinlimab is the first listed.
NCT05633355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05633355 about?
NCT05633355 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)". The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
What is the current status of trial NCT05633355?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2023-01-30. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT05633355?
The interventions under investigation include: Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT05633355?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.